secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0000950103-24-004017
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen reports FY2023 loss of $95.9M; plans BLA submission for PRGN-2012 in H2 2024
--------------------------------------------------------------------------------

- FY2023 revenue $6.2M, down 77% YoY; net loss $95.9M ($0.39 loss per share).
- Cash and investments $62.9M; SG&A down 16% to support cost containment.
- Plans to submit BLA for PRGN-2012 under accelerated approval in H2 2024; potential launch 2025.
- PRGN-2009 IND cleared Phase 2 in cervical cancer; interim data for PRGN-3006 and PRGN-3007 expected H2 2024.
- Recorded $10.4M goodwill impairment charge for Exemplar subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324004017/0000950103-24-004017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324004017/dp208564_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-004017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer